Restoring Facial Volume After GLP-1 Weight Loss With Radiesse

The goal of this clinical trial is to evaluate the potential of Calcium Hydroxylapatite (CaHA) to restore facial volume and improve skin quality in patients with GLP-1 receptor agonist-associated facial volume loss. Participants will: * Schedule first dose of a prescribed GLP-1 receptor agonist drug to coincide with the baseline visit of this study * Be randomly assigned to one of two groups (Group A will receive off-label injections of hyperdiluted CaHA at Month 0. Group B will receive on-label injections of CaHA after serving as a control group through Month 6) * Have clinical photos taken at each office visit to track progress

NCT Number	NCT07419854
Lead Sponsor	Kalpna Kay Durairaj, MD, FACS Collaborators: Merz Aesthetics Inc.
Conditions	Volume Loss (Soft Tissue Ptosis or Atrophy )
Enrollment	48 participants
Start Date	2026-02
Primary Completion	2027-08 (estimated)
Study Completion	2027-09 (estimated)
Updated on ClinicalTrials.gov	2026-02-19